J&J files European marketing application for expanded use of Darzalex

|About: Celgene Corporation (CELG)|By:, SA News Editor

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutica NV has filed a supplemental marketing application in Europe seeking approval to use DARZALEX (daratumumab), combined with Celgene's (NASDAQ:CELG) REVLIMID (lenalidomide) and dexamethasone, to treat multiple myeloma patients who are not candidates for high-dose chemo and autologous stem cell transplant.

Janssen in-licensed global rights to daratumumab from Genmab A/S (OTCPK:GNMSF) in August 2012.

Subscribe for full text news in your inbox